1. Home
  2. NGNE vs REF Comparison

NGNE vs REF Comparison

Compare NGNE & REF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$38.24

Market Cap

744.9M

Sector

Health Care

ML Signal

HOLD

Logo Reformation Inc. Common Stock

REF

Reformation Inc. Common Stock

N/A

Current Price

$14.27

Market Cap

886.1M

ML Signal

N/A

Company Overview

Basic Information
Metric
NGNE
REF
Founded
2003
N/A
Country
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Apparel
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
744.9M
886.1M
IPO Year
2014
2026

Fundamental Metrics

Financial Performance
Metric
NGNE
REF
Price
$38.24
$14.27
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$63.57
N/A
AVG Volume (30 Days)
193.8K
387.6K
Earning Date
05-08-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
0.93
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.93
$12.83
52 Week High
$43.66
$17.26

Technical Indicators

Market Signals
Indicator
NGNE
REF
Relative Strength Index (RSI) 56.17 43.64
Support Level $18.00 $12.83
Resistance Level $42.84 $15.72
Average True Range (ATR) 2.40 0.88
MACD -0.07 -0.01
Stochastic Oscillator 51.32 47.15

Price Performance

Historical Comparison
NGNE
REF

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

About REF Reformation Inc. Common Stock

Reformation Inc sells apparel and accessories through its website, company-owned retail stores, wholesale channels, and other distribution channels in the United States and internationally. Its product portfolio includes dresses, bottoms, tops, sweaters, and accessories. The company focuses on womenswear and sources materials and products through its supply chain operations. The majority of the company's revenue was derived from the sale of its apparel and accessories, including clothing, shoes, and bags, through e-commerce and retail. Geographically, the maximum revenue is generated from the United States.

Share on Social Networks: